The Strongest Dose of Wegovy and How You Get There

Step 1: Starting low on purpose, the logic behind 0.25mg

Every Wegovy journey opens at 0.25mg. That is not a therapeutic amount in the weight-loss sense; it is a settling-in dose that gives your gut time to adapt to semaglutide before the doses climb. Nausea, the side effect patients ask our prescribers about most often, is strongly related to how quickly the dose rises. Starting cautiously makes the whole journey more manageable.

After roughly four weeks at 0.25mg, the schedule moves to 0.5mg. From there it progresses through 1.0mg, then 1.7mg, and finally 2.4mg, the dose that was, until 2026, the recognised maintenance level for weight management. Each step takes about a month. By the time you reach 2.4mg you have been on treatment for roughly twenty weeks. The full Wegovy dose schedule covers each rung in detail if you want to understand what happens at each stage.

Throughout this period your prescriber reviews your progress. Side effects, any medical changes, your actual weight trajectory, all of it informs whether to continue, pause or adjust. The titration is not automatic. It is a clinical process.

Step 2: The 7.2mg option, what the MHRA's 2026 approval actually means

On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen for adults with a BMI of 30 or above. This was the second step in expanding Wegovy's dosing ceiling: the 7.2mg maintenance dose had been permitted since January 2026 using three 2.4mg pens weekly, but the single-pen format is simpler and less prone to dosing errors.

The evidence behind it is meaningful. Trials reported an average weight loss of around 20.7% over 72 weeks at the 7.2mg dose, a figure that narrows the gap significantly with the highest licensed tirzepatide dose. You can read about how the two medicines compare on the Wegovy overview page.

An important boundary: the 7.2mg pen is licensed specifically for adults with a BMI of 30 or above for weight management. It does not carry approval for lower BMI groups or for Wegovy's separate cardiovascular indication. Whether the strongest dose is appropriate for a particular patient is a prescriber decision made in light of their full clinical picture, not a choice made by selecting a product on a website.

For context on how this highest dose compares with the earlier maintenance strength, the page on whether 2.4mg is strong explains what that dose achieves and why the ceiling was extended.

Step 3: Reaching and staying at the highest dose, what that looks like in practice

If a prescriber judges 7.2mg appropriate, the move from 2.4mg follows the same cautious principle as every earlier step: one month at a time, with clinical review before progressing. The pen itself is designed for straightforward use, it is a single pre-set weekly injection with an auto-dosing mechanism and a covered needle that locks after use.

Storage is the same as for every Wegovy pen: refrigerated between 2°C and 8°C. A good habit many patients settle into is keeping it in the fridge door, away from the colder back shelf where things can accidentally freeze. The Patient Information Leaflet details the exact room-temperature window for times when refrigeration is not possible, always check the leaflet rather than relying on general advice.

NICE's appraisal of semaglutide under TA875 recommends treatment continues only if meaningful weight loss is achieved; if fewer than 5% of body weight has been lost after six months at the maintenance dose, continuation is reviewed. That principle applies at 7.2mg just as it does at 2.4mg. The strongest dose is only valuable if it is working for you.

What the highest dose is not, clearing up the dose questions we hear often

A question that comes up regularly: does a higher dose always mean better results? Not necessarily. Many people achieve their target weight loss well before 7.2mg and stay at whichever maintenance dose is doing the job. The ceiling exists for those who plateau or who need greater effect, not as a default destination.

It is also worth knowing that the Wegovy tablet (oral semaglutide, approved by the MHRA in June 2026) follows a completely different dose schedule and is a separate licensed product. Its maximum maintenance dose of 25mg is not comparable to the injection's 7.2mg; the numbers reflect different formulations and routes of administration.

Questions about where you might sit on the dose ladder are answered at consultation. If you want to understand the earlier doses before that conversation, the pages on 1mg and 1.7mg each explain what those stages are designed to do. And if you are curious about how the journey begins, there is a detailed look at whether 0.5mg is meaningfully stronger than 0.25mg.

For anyone thinking about starting Wegovy privately, the treatment consultation at nume is the right first step. A GPhC-registered prescriber reads every application the same day, a real clinician, looking at your specific details. That is the only way to know which dose, if any, is clinically appropriate for you.